Chengdu Olymvax Biopharmaceuticals Inc. Class ASSE: 688319

"Chengdu Olymvax Biopharmaceuticals Inc."Semi-annual Report for 2026

Aug 18, 2026 · Issued by Chengdu Olymvax Biopharmaceuticals Inc. Class A via Shanghai Stock Exchange

Semi-annual Report for 2026

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Chengdu Olymvax Biopharmaceuticals Inc. Class A

"Chengdu Olymvax Biopharmaceuticals Inc."Announcement on Convening the 2026 Semi-annual Performance BriefingAug 11
"Chengdu Olymvax Biopharmaceuticals Inc."Announcement on Pledge of Certain Shares Held by Shareholders Holding More Than 5% of the SharesAug 8
"Chengdu Olymvax Biopharmaceuticals Inc."Voluntary Disclosure Announcement on the Unblinding Results of the Phase III Clinical Trial of Recombinant Staphylococcus Aureus Vaccine (E. coli)Jul 11
"Chengdu Olymvax Biopharmaceuticals Inc."Announcement on Voluntary Disclosure of Winning the Second Prize of the 2025 National Technological Invention AwardJul 9

All Chengdu Olymvax Biopharmaceuticals Inc. Class A news releases